Slayback Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Slayback Pharma's estimated annual revenue is currently $25.3M per year.
- Slayback Pharma received $60.0M in venture funding in January 2017.
- Slayback Pharma's estimated revenue per employee is $201,000
- Slayback Pharma's total funding is $110M.
Employee Data
- Slayback Pharma has 126 Employees.
- Slayback Pharma grew their employee count by 0% last year.
Slayback Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Alliance Management | Reveal Email/Phone |
2 | VP Operations | Reveal Email/Phone |
3 | VP, Business Development | Reveal Email/Phone |
4 | VP, Portfolio Innovation and Strategy | Reveal Email/Phone |
5 | VP Sales | Reveal Email/Phone |
6 | VP - Quality & Compliance | Reveal Email/Phone |
7 | VP - R&D Head | Reveal Email/Phone |
8 | VP, Finance | Reveal Email/Phone |
9 | Director, National Accounts GPO & Trade | Reveal Email/Phone |
10 | Chief Commercial Officer | Reveal Email/Phone |
Slayback Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Slayback Pharma?
Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.
keywords:N/A
$110M
Total Funding
126
Number of Employees
$25.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Slayback Pharma News
Eagle previously asserted several Orange Book-listed patents against Slayback Pharma LLC, Apotex Inc. (Apotex) et al, Mylan Laboratories...
Slayback Pharma is a Princeton, NJ headquartered, speciality pharmaceutical company focused on the development and commercialization of...
HYDERABAD: The Telangana government on Sunday said US-based complex generic and specialty drugs player, Slayback Pharma, will be investing...
PRINCETON, N.J., June 25, 2021 /PRNewswire/ -- Slayback Pharma LLC, a Princeton, NJ based specialty pharmaceutical company, announced today the appointment of Pete A. Meyers as its Chief Financial Officer. Pete has nearly three decades of rich experience in the pharmaceutical industry straddl ...
PRINCETON, N.J., Feb. 4, 2021 /PRNewswire/ -- Slayback Pharma LLC announces that it has launched Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) 1 mg/20 mcg and fulfilled customer orders for the product. With the launch, Slayback has effectively secu ...
Other Companies in Princeton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 127 | 6% | N/A |
#2 | $7.5M | 127 | 10% | N/A |
#3 | $32.1M | 128 | 6% | N/A |
#4 | $18.7M | 129 | -8% | N/A |
#5 | $18.7M | 129 | 7% | N/A |
Slayback Pharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-01-06 | $60.0M | Undisclosed | KKR | Article |